Molecular Diagnostics at the Point of Care Market Research Report 2025: Comprehensive Five-Year Forecasts - Displacing Frontline Test Protocols and Saving Money
Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care 2025-2029: By Application, Technology, Place, Product and Country, with Executive Guides and Analysis" has been added to ResearchAndMarkets.com's offering.
Molecular Diagnostics at the Point of Care is on the brink of unprecedented growth, offering transformative changes in healthcare outcomes and cost-efficiency. This burgeoning market segment is being propelled by advancements in technology and increasing demand for rapid, reliable testing solutions available right at the patient's bedside.
Recent data indicates an impressive upward trajectory in market performance, driven in part by major players who are consistently reporting robust growth figures. One of the key catalysts for this surge is the technology's capability to significantly reduce costs while simultaneously enhancing diagnostic outcomes. Importantly, it plays a vital role in combating Anti-Microbial Resistance, presenting a compelling case for its wider adoption.
With a market poised to potentially disrupt traditional testing protocols, stakeholders are keen on understanding both the challenges and future outlooks this development entails. This comprehensive report offers an in-depth forecast of the market size over the next five years, enabling stakeholders to align strategies and optimize operations effectively.
Equipped with this knowledge, industry experts can gain a competitive edge, leveraging this detailed analysis to inform decision-making processes. Complementing the report, additional specific data and expert assistance are readily available, ensuring that professionals have access to precise and actionable insights without incurring extra charges.
For a deeper dive, all report data can be accessed in Excel format upon request, providing a versatile tool for robust investment decisions and accurate valuations. This flexibility ensures that financial assessments and strategic planning are grounded in the most up-to-date information.
As the Molecular Diagnostics at Point of Care market continues to evolve, staying informed and prepared is more critical than ever. This report serves as an essential resource for organizations looking to harness these market developments and drive forward-thinking strategies in the healthcare domain.
Key Topics Covered:
1 Market Guides1.1 Strategic Situation Analysis1.2 Guide for Executives, Marketing and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors2 Introduction and Market Definition2.1 What are Molecular Diagnostics at the Point of Care?2.2 The Diagnostics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare Spending3 Instrumentation, Automation and Diagnostic Trends3.1 Instrumentation and Automation3.1.1 Traditional Automation and Centralization3.1.2 The New Automation, Decentralization and Point Of Care3.1.3 Instruments Key to Market Share3.1.4 Bioinformatics Plays a Role3.1.5 PCR Takes Command3.1.6 Next Generation Sequencing Fuels a Revolution3.1.7 NGS Impact on Pricing3.1.8 Whole Genome Sequencing, A Brave New World3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.2.1 Hospital vs. Central Lab4.3.3 Physician Office Lab's4.3.4 Physician's and POCT5 Profiles of Key MDx Companies5.1 Abbott Laboratories5.2 Abionic5.3 Accelerate Diagnostics5.4 Access Bio5.5 Ador Diagnostics5.6 ADT Biotech5.7 Akonni Biosystems5.8 Alveo Technologies5.9 Anitoa5.10 Applied BioCode5.11 Aureum Diagnostics5.12 Aus Diagnostics5.13 Autonomous Medical Devices5.14 Baebies5.15 Beckman Coulter Diagnostics (Danaher)5.16 Becton, Dickinson and Company5.17 Binx Health5.18 Biocartis5.19 BioFire Diagnostics (bioMerieux)5.20 bioMerieux Diagnostics5.21 Bio-Rad Laboratories, Inc5.22 Bosch Healthcare Solutions GmbH5.23 Cepheid (Danaher)5.24 Credo Diagnostics Biomedical5.25 Cue Health5.26 Curetis (OpGen)5.27 Detect5.28 Diagenode Diagnostics (Hologic)5.29 Diasorin S.p.A.5.30 DNAe5.31 Domus Diagnostics5.32 Enzo Biochem5.33 Eurofins Scientific5.34 Fluxergy5.35 Fusion Genomics.5.36 Genedrive5.37 Genetic Signatures5.38 GenMark Dx (Roche)5.39 Genomadix5.40 Getlabs5.41 Global Access Diagnostics5.42 Grip Molecular Technologies5.43 Hologic5.44 Immunexpress5.45 Inflammatix5.46 Invetech5.47 Iollo5.48 J&J Innovative Medicine5.49 Karius5.50 Lucira Health (Pfizer)5.51 LumiraDx5.52 Maxim Biomedical5.53 Meep5.54 Meridian Bioscience5.55 Millipore Sigma5.56 Molbio Diagnostics5.57 NanoDx5.58 Nanomix5.59 Novacyt5.60 Novel Microdevices5.61 Novus Diagnostics5.62 Nuclein5.63 OnsiteGene5.64 Operon5.65 OraSure Technologies5.66 Oxford Nanopore Technologies5.67 Panagene5.68 Prenetics5.69 Primerdesign (Novacyt)5.70 Prominex5.71 Proof Diagnostics5.72 Qiagen5.73 QuantuMDx5.74 QuidelOrtho5.75 R-Biopharm AG5.76 Response Biomedical5.77 Revvity5.78 Roche Diagnostics5.79 Salignostics5.80 SD Biosensor5.81 Seegene5.82 Sekisui Diagnostics5.83 Siemens Healthineers5.84 Sona Nanotech5.85 SpeeDx5.86 T2 Biosystems5.87 Talis Biomedical5.88 Thermo Fisher Scientific5.89 Uniogen5.90 Veramarx5.91 Veredus Laboratories5.92 XCR Diagnostics5.93 Zhejiang Orient Gene Biotech6 Market Trends6.1 Factors Driving Growth6.1.1 New Genotypes Creating New Markets6.1.2 Aging Population a Boon for All Diagnostics6.1.3 Developing World Driving ID Dx Growth6.1.4 Point of Care - Why Centralization is Losing Steam6.1.5 Self Testing6.1.6 The Need for Speed6.2 Factors Limiting Growth6.2.1 Lower Costs6.2.2 Infectious Disease is Declining6.2.3 Wellness Hurts6.2.4 Economic Growth improves Living Standards7 Molecular Dx - Infectious Disease Recent Developments7.1 Recent Developments - Importance and How to Use This Section7.1.1 Importance of These Developments7.1.2 How to Use This Section7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform7.3 Roche receives FDA clearance for STI at POC7.4 Smartphone-Enabled Platform Transforms POC Testing7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch7.6 A low-cost CRISPR-based paper strip test for flu7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/257.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact7.11 DiagMetrics Developing Breath Assays7.12 Fortis Life Sciences Acquires IPOC7.13 Domus Diagnostics Wins NIH RADx Tech Contract7.14 Llusern Scientific to Launch POC MDx UTI Panel7.15 Altratech Enters POC MDx Testing Space with Unique Tech7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit7.20 NanoDx Prepares for Point-of-Care Commercialization7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection7.22 MicroGEM to Expand 30-Minute RT-PCR System7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument7.24 Diagnostics for the Real World Third-Generation POC Platform7.25 Salignostics Closes Funding Round7.26 Cue Health Targets DTC Market in 20227.27 Grip Molecular Developing Home Respiratory Panel7.28 Mainz Biomed Developing Home ColoAlert Assay7.29 MFB Fertility Closes Series A Financing Round7.30 Home Test Company Prenetics to go Public7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform7.33 Talis Biomedical Discusses Point-of-Care7.34 Roche to Acquire GenMark Diagnostics for $1.8B7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization7.36 Hologic to Acquire Mobidiag7.37 Lucira Health Focuses on User Friendly Approach to Home Testing7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M7.41 Mammoth Biosciences Developing Pathogen Detection Tech7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests7.43 Scanogen Developing 90 Minute Infection Test7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark7.49 Lumos Diagnostics Closes $15M Series A Funding
For more information about this report visit https://www.researchandmarkets.com/r/vbcfje
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Global Industry Growth, Competitive Landscape, Opportunities, and Challenges
The Global Oral Dispensing Syringe Market Size is projected to surge from USD 445 Million in 2025 to USD 664 Million by 2034, driven by a CAGR of 5.9%. Key growth factors include rising awareness of accurate medication dosing, the growing elderly population, and increased demand in home healthcare. Oral Dispensing Syringe Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Oral Dispensing Syringe Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" has been added to offering. The Global Oral Dispensing Syringe Market is poised for robust growth, with its size projected to reach USD 445 million by 2025. The market's expansion is anticipated at a notable CAGR of 5.9%, culminating in a valuation of USD 664 million by 2034. This sector's significance in healthcare is underscored by the increasing demand for administering liquid medications to pediatric, geriatric, and special needs patients, driven by the necessity for accurate dosage, minimized waste, and enhanced medication adherence. Healthcare providers and caregivers are increasingly adopting oral dispensing syringes to ensure patient safety. The surge in chronic conditions and the burgeoning home healthcare sector further fuel the demand for these syringes. Manufacturers are keenly developing designs that are user-friendly, BPA-free, and latex-free to meet stringent safety and compliance standards. This focus on safe, compliant products is accelerating their adoption. Innovation in the market is continuous, with features like color-coded syringes, easy-to-read measurement markings, and ergonomic designs enhancing user experience. Recent advancements include integrated caps and tamper-evident seals, ensuring medication integrity. Additionally, the expanding application of these syringes in veterinary medicine is broadening market appeal. Collaborations between pharmaceutical companies and syringe manufacturers are pivotal in driving product development and expanding market penetration. The ongoing emphasis on patient safety, precise dosing, and convenience underscores the essential role of oral dispensing syringes in modern medication delivery practices. Key Takeaways Increasing awareness around proper medication dosing fuels demand for oral dispensing syringes. Aging populations and rising chronic disease cases propel market growth. Regulatory encouragement for BPA-free and latex-free syringes increases adoption. Home healthcare and telemedicine trends positively impact syringe usage. Innovations include features like tamper-evident seals and color-coded options for enhanced safety. Syringe manufacturers' partnerships with pharmaceutical companies stimulate innovation. Veterinary uses represent a growing niche market. Environmentally friendly designs attract eco-conscious consumers. Ergonomic design and clear markings improve user convenience. Integrated caps in syringes heighten safety. Direct-to-consumer sales channels enhance accessibility. Growth is supported by elevated healthcare investment and infrastructure improvements globally. Advances in technology allow customization for specific medications. Strong adherence to industry standards and certifications guarantees product reliability. Increased R&D investments by leading firms sustain the market's expansion. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $445 Million Forecasted Market Value (USD) by 2034 $745 Million Compound Annual Growth Rate 5.9% Regions Covered Global Companies Featured Becton, Dickinson and Company Terumo Corporation Medline Industries Cardinal Health Comar, LLC Weigao Group Gerresheimer AG West Pharmaceutical Services, Inc. Henke-Sass, Wolf GmbH Jiangsu Jichun Medical Devices Vygon SA Thermo Fisher Scientific ProMedica NeoMed, Inc. EXEL International For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Oral Dispensing Syringe Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
an hour ago
- Yahoo
Electric Propulsion Gains Traction and Fuels Opportunities, Supporting Long-Haul Space Missions with Fuel Efficiency
The Rocket Engines Market, poised at USD 5.2 billion in 2025, is set to soar with a CAGR of 19.6% reaching USD 26.2 billion by 2034. This growth is driven by innovations in reusable and high-efficiency engines, increased global investments, and demand for sustainable propulsion technologies in aerospace and defense. Rocket Engines Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Rocket Engines Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (Physically Powered, Chemically Powered, Electrically Powered, Thermal, Nuclear Rocket Engines), By Product Type, By Application" has been added to offering. The global Rocket Engines Market, valued at USD 5.2 billion in 2025, is projected to achieve a staggering growth by a CAGR of 19.6%, reaching USD 26.2 billion in 2034. This dynamic market is integral to the aerospace and defense industries, driving both innovative space launch vehicles and precision intercontinental missiles. With advancements in propulsion technologies such as liquid, solid, hybrid, and electric engines, there is a growing demand for efficient, reliable, and sustainable solutions. Noticeable developments in 2024 have brought advancements in reusable and high-efficiency engine technologies. Companies like SpaceX and Blue Origin are leading with methane-fueled engines offering cleaner combustion and superior reusability. The integration of 3D-printed components has not only accelerated the prototyping process but has also reduced production costs significantly, opening the industry to new players. Defense sectors are focusing on engineering compact rocket motors and versatile propulsion systems for future hypersonic applications. Nations like India, China, and the UAE are intensifying their focus on local engine developments for civilian and military use. Hybrid propulsion systems are gaining traction, given their balanced performance attributes. Moreover, environmental concerns have spurred research into green propellants. The year's developments indicate a shift towards efficiency, sustainability, and wider accessibility in engine design. Looking toward 2025, the market is poised for rapid transformation. Electric propulsion will play a critical role in deep space missions, enhancing fuel efficiency and mission duration. Reusable engines are set to reshape commercial launch economics, while geopolitical priorities will likely drive advances in military applications. The development of compact engines will bolster the proliferation of micro-launch systems. Emerging markets and new entrants are intensifying global competition, particularly across the Asia-Pacific and Middle Eastern regions. Enhanced collaborations between commercial entities and national space agencies are reshaping R&D efforts. Innovations in cryogenic and staged combustion systems promise to push performance limits further. Sustainability continues to be a pivotal concern, guiding initiatives toward the development of non-toxic propellants and reducing space-borne and terrestrial emissions. Key Insights in the Rocket Engines Market Methane-fueled reusable engines are gaining ground for their economic and environmental benefits. 3D printing accelerates design cycles, reducing costs and boosting innovations. Electric propulsion is pivotal for long-duration, efficient satellite and deep space missions. Hybrid propulsion is emerging as a versatile alternative, balancing control and power. Small, modular engines are facilitating micro-launch capabilities for both commercial and defense applications. Satellite launches are bolstering the demand for reliable, high-frequency propulsion systems. National security needs are driving investments in advanced missile propulsion technology. Space commercialization encourages cutting-edge, deep-space engine designs. Government initiatives and international partnerships are enhancing next-gen propulsion R&D. High development costs and stringent regulations remain barriers to market entry. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value in 2025 5.2 Billion Forecasted Market Value by 2034 26.2 Billion Compound Annual Growth Rate 19.5% Regions Covered Global Companies Featured Aerojet Rocketdyne Holdings Inc. Space Exploration Technologies Corp. Northrop Grumman Corporation Mitsubishi Heavy Industrie Ltd. Blue Origin LLC IHI Corporation National Aeronautics and Space Administration (NASA) Lockheed Martin Corporation China Aerospace Science and Technology Corporation (CASC) Roscosmos Skyroot Aerospace Gilmour Space Technologies NextAero Deep Blue Aerospace JZYJ Space Technology Mitsubishi Heavy Industries Tamadic Co Ltd CASC Reaction Engines Roll- Royce Limited Skyrora Westcott's Space Cluster Orbital Propulsion Centre Safran Aircraft Engines Roxel Pangea Aerospace AVIO ARCA space ISAR Aerospace Serbian Aerospace Industry EDePro GKN Aerospace Boeing Defence Space & Security Raytheon Maxar Space SpaceX Orbital ATK Virgin Galactic Rocket Lab Avibras Industria Aeroespacial S/A LIA Aerospace Israel Aerospace Industries New Rocket Marcom Aeronautics & Space The Boeing Company Rocket Engines Market Segmentation By Type Physically Powered Chemically Powered Electrically Powered Thermal Nuclear Rocket Engines By Product Type Liquid Rocket Engines Solid Rocket Engines By Application Spacecraft Ballistic Missiles Others By Geography North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Rocket Engines Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
In Vitro Diagnostics Market Size to Exceed USD 132.18 Bn by 2034
According to Precedence Research, the global in vitro diagnostics (IVD) market size is expected to exceed USD 132.07 billion by 2034, increasing from USD 104.01 billion in 2025, with a CAGR of 2.30% between 2025 and 2034. Growth is fueled by rising chronic disease prevalence, demand for early detection, and rapid adoption of advanced molecular testing technologies. Ottawa, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The worldwide in vitro diagnostics market size accounted for USD 102.05 billion in 2024, and is predicted to grow from USD 104.01 billion in 2025 to approximately USD 132.07 billion by 2034. The growing awareness about the early detection of diseases and the growing prevalence of chronic diseases drive market growth. Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for Before You Buy – Get the Sample Report@ In Vitro Diagnostics Industry – Strategic Insights In terms of revenue, the in vitro diagnostics market has been calculated at USD 104.01 billion in 2025. It is anticipated to reach over USD 132.07 billion by 2034. North America captured a 42% revenue share of the global market in 2024. Asia Pacific is expected to grow at a significant CAGR between 2025 and 2034. By product, the reagents segment held the major market share of 66.07% in 2024. By product, the instruments segment is expanding at a solid CAGR from 2025 to 2034. By test location, the point-of-care segment held a significant share in 2024. By test location, the home care segment is anticipated to witness considerable growth from 2025 to 2034 By technology, the molecular diagnostics segment contributed the largest market share of 33.06% in 2024. By technology, the immunoassay segment is projected to grow at a considerable CAGR from 2025 to 2034. By application, the infectious disease segment accounted for the biggest market share of 52.53% in 2024. By application, the oncology segment is growing at a notable CAGR between 2025 and 2034. By end user, the hospital segment held the largest market share of 37.89% in 2024. In Vitro Diagnostics Market Revenue (USD Million) By Product Type 2022-2024 Product 2022 2023 2024 Instruments 28,950.5 26,909.55 25,379.75 Reagents 75,883.9 70,996.28 67,404.76 Services 10,654.3 9,861.36 9,264.58 In Vitro Diagnostics Market Revenue (USD Million) By Technology 2022-2024 Technology 2022 2023 2024 Immunoassay 34,688.2 32,433.72 30,774.22 Hematology 6,827.4 6,345.41 5,984.69 Clinical Chemistry 20,236.7 18,978.14 18,061.02 Molecular Diagnosis 38,255.7 35,662.26 33,736.25 Coagulation 4,680.5 4,328.27 4,061.72 Microbiology 6,384.9 5,916.29 5,563.15 Others 4,415.3 4,103.12 3,868.03 In Vitro Diagnostics Market Revenue (USD Million) By Application 2022-2024 Application 2022 2023 2024 Infectious Diseases 61,149.9 56,833.27 53,602.44 Diabetes 9,146.6 8,475.36 7,969.48 Oncology 8,727.7 8,323.38 8,055.14 Cardiology 9,104.3 8,538.03 8,125.43 Nephrology 6,633.3 6,127.88 5,744.71 Autoimmune Diseases 5,350.6 4,987.83 4,718.45 Drug Testing 3,986.6 3,757.30 3,593.52 Others 11,389.6 10,724.14 10,239.92 Available for Instant Download – Order This Premium Market Study Today@ In Vitro Diagnostics Market Overview In vitro diagnostics (IVD) are tests conducted on samples retrieved from human bodily tissues and fluids. IVD performs on biological samples like tissue, blood, urine, and others, and tests are performed in the laboratory. Tests help to diagnose various infections, diseases, & other health issues, and monitor patient health. IVD helps in the early detection of diseases, avoids the spreading of diseases, and enhances patient care. The common IVD tests are COVID-19, HIV tests, pregnancy tests, blood glucose monitoring, and many more. Factors like a rise in personalised medicines, increasing awareness about the early detection of diseases, growing cardiovascular diseases, and technological advancements in IVD contribute to the in vitro diagnostics market. Top Types of IVD Technologies in 2025: Technology Working Principle Uses ELISA Capturing the antigen-antibody reaction Autoimmune disorder HIV Lyme Disease NGS DNA fragmentation and parallel sequencing Cancer Genetic disorders Infectious diseases CLIA The binding antibody and the corresponding antigenChemiluminescence reactions Hormone imbalances Tumor detection Diabetes Hypertension PCR/RT-PCR Amplification of DNA & RNA Genetic disorder Infectious diseases Flow Cytometry Laser-based techniques for the analysis of cells Blood disorders Immune system problems Myelodysplastic syndromes Lateral Flow Sample amplification and target binding Pregnancy Respiratory infections Mosquito-borne diseases Sexually transmitted infections ➤ In Vitro Diagnostics Market Major Trends: Advanced Lateral Flow Tests (LFTs) Beyond COVID-19Evolved LFTs are now capable of detecting a wide array of substances—from vitamin D and iron to stroke markers—using novel samples like fingerprint sweat or pet vomit. Their versatility is rapidly expanding across healthcare, environmental, and even animal diagnostics. Integrated Point-of-Care and At-Home Nutritional DiagnosticsInnovations like smartphone-compatible devices (e.g., Cornell's NutriPhone) can measure iron, vitamin A, D, and B12 from just a finger-prick in minutes—indicating a shift toward compact, multipurpose diagnostics useful in both clinics and homes. Artificial Intelligence–Enhanced Digital Nucleic Acid Amplification (dNAAT)Cutting-edge techniques such as digital PCR (dPCR) and digital LAMP (dLAMP), combined with AI-powered image analysis, are enhancing diagnostic precision and sensitivity. These advancements pave the way for scalable, faster, and more accurate molecular testing, even at the point of care. In Vitro Diagnostics Market Opportunity What is the Opportunity for the In Vitro Diagnostics Market? The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases demand for in vitro diagnostics for early detection of diseases. The increasing patient demand for early detection of chronic diseases increases demand for IVD tests. The increasing demand for tracking the progression of chronic diseases increases the adoption of IVD for managing disease effectively and adjusting treatment plans. The increasing development of personalised treatment requires IVD technologies. The availability of point-of-care testing increases adoption of IVD for efficient management of chronic conditions. The increasing awareness of early disease detection and the increasing demand for regular health check-ups increase the adoption of IVD. The growing prevalence of chronic diseases creates an opportunity for the growth of the in vitro diagnostics market. In Vitro Diagnostics Market Challenges and Limitations and Challenges: Why High Development Cost Limitation for the In Vitro Diagnostics Market? Despite several benefits of in vitro diagnostics in various disease diagnoses, the high development cost restricts the market growth. Factors like the need for extensive clinical validation, the complex nature of IVD platforms, stricter regulation, high investment in R&D, and intensive clinical trials are responsible for high development costs. The need for high investment in personnel, equipment, and reagents directly affects the market. The complexity of IVD technologies and lengthy development cycles increases the production costs. The stricter regulations for the development of IVD tests require a high cost. The need for extensive compliance, documentation, and quality assurance requires a high cost. The requirement of specialized materials and precision manufacturing increases the production cost. The high development cost hampers the growth of the in vitro diagnostics market. Scope of the In Vitro Diagnostics Market Report Attributes Key Statistics Market Size in 2025 USD 104.10 Billion Market Size in 2030 USD 117.18 Billion Market Size in 2032 USD 124.66 Billion Market Size by 2034 USD 132.07 Billion Growth Rate 2025-2034 CAGR of 2.30% Base Year 2024 Forecast Period 2025 to 2034 Historical Data 2021 to 2023 Largest Regional Market (2024) North America – 42% revenue share Fastest Growing Regional Market Asia Pacific Segments Covered Product, Technology, Application and Regions Regions Covered North America, APAC, Europe, Latin America, MEAN, Rest of the World Key Players Covered Alere, Inc., Hoffmann-La Roche Ltd., Arkray,Beckman Coulter, Becton Disckinson, Bio-Rad laboratories, Danaher, Sysmex Corporation, Abbott Laboratories and other ➡️ Become a valued research partner with us ☎ How Big is the U.S. In Vitro Diagnostics (IVD) Market? According to Precedence Research, the U.S. in vitro diagnostics (IVD) market size was evaluated at USD 34.98 billion in 2024 and is expected to rise from USD 35.43 billion in 2025 to approximately USD 42.55 billion by 2034, at a CAGR of 2.20% from 2025 to 2034. The Complete Study is Immediately Accessible | Download the Sample Pages of this Report@ U.S. In Vitro Diagnostics Market Key Takeaways The U.S. in vitro diagnostics market reached USD 34.98 billion in 2024. It is projected to hit around USD 42.63 billion by 2034. The market is growing at a CAGR of 2% from 2025 to 2034. By product, the reagents segment held the highest share of 67% in 2024. By test location, the point-of-care segment dominated the market in 2024. By technology, the Immunoassay segment is expected to grow at a significant CAGR from 2025 to 2034. By application, the infectious diseases segment dominated the market with the biggest market share in 2024. By application, the oncology segment is expected to witness the fastest CAGR of growth during the forecast period of 2025-2034. By end user, the hospital segment held the dominating share of the market in 2024. U.S. In Vitro Diagnostics Market Leading Companies Alere, Inc. Beckman Coulter BD Bio-Rad laboratories Danaher Abbott Laboratories Thermo Fisher Scientific Inc. bioMérieux, Inc Quest Diagnostics Illumina, Inc. Get Immediate Access – Secure Your Copy of This Premium Research Report@ Which Region Dominated the In Vitro Diagnostics Market? North America dominated the in vitro diagnostics market in 2024. The well-established healthcare infrastructure, like research centers, modern clinical laboratories, and hospitals, increases the adoption of IVD. The ongoing technological innovations like digital health integration, high-throughput systems, and lab-on-a-chip equipment in IVD help the market growth. The increasing prevalence of infectious and chronic diseases increases the adoption of IVD. The increasing healthcare spending and focus on personalised medicine increase the adoption of IVD. The presence of major players like BD, Abbott, and Thermo Fisher Scientific drives the market growth. Why Asia Pacific Experiencing the Fastest Growth in the In Vitro Diagnostics Market? Asia Pacific is experiencing the fastest growth in the market during the forecast period. The growing prevalence of chronic diseases like cancer, diabetes, and cardiovascular diseases increases the adoption of IVD. The growing government investment in healthcare infrastructure and increasing spending on diagnostics increases demand for IVD, helping the market growth. The increasing awareness about the early detection of diseases and the growing expansion of healthcare facilities like clinics & hospitals increases adoption of IVD, supporting the overall growth of the market. 'The integration of AI with molecular diagnostics will reshape IVD workflows over the next decade, improving test turnaround times and accuracy, particularly in decentralized settings,' said Deepa Pandey, Principal Consultant at Precedence Research. In Vitro Diagnostics Market Segmentation Analysis: Product Analysis: Why did Reagent Segment Dominate the In Vitro Diagnostics Market? The reagent segment dominated the in vitro diagnostics market in 2024. The compatibility of reagents with various diagnostics platforms, like point-of-care, clinical laboratories, and hospitals, helps the market growth. The growth in personalised medicine increases the adoption of reagents. The growth in diagnostics like oncology, infectious diseases, and chronic diseases increases the adoption of reagents. The growing utilization of molecular diagnostic techniques increases demand for reagents, driving the overall growth of the market. The instruments segment is the fastest-growing in the market during the forecast period. The growing prevalence of chronic diseases like cardiovascular conditions, diabetes, and cancer increases demand for instruments for early detection. The increasing focus on early detection of diseases and timely treatment increases demand for instruments. The ongoing innovations in diagnostic technologies and the expansion of point-of-care testing support the market growth. Technology Analysis: How Immunoassay Segment Held the Largest Share in the In Vitro Diagnostics Market? The immunoassay segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing detection of various analytes like proteins, drugs, hormones, and antibodies increases the adoption of immunoassays. The increasing demand for ELISA and CLIA immunoassays helps the market growth. The increasing demand for POC testing and the increasing availability of central labs increase the adoption of immunoassays. The increasing risks of infectious diseases and chronic diseases increase demand for immunoassay-based diagnosis, driving the overall market growth. The molecular diagnostics segment is experiencing the fastest growth in the market during the forecast period. The growing utilization of techniques like next-generation sequencing & PCR for early disease diagnosis helps the market growth. The increased spread of infectious diseases increases the adoption of molecular diagnostics to control the spread of disease. The increasing development of personalised medicine and growth in at-home testing & point-of-care fuels demand for molecular diagnostics, supporting the overall market growth. Application Analysis: Which Application Segment Dominated the In Vitro Diagnostics Market? The oncology segment dominated the in vitro diagnostics market in 2024. The increasing prevalence of cancer increases demand for IVD for accurate diagnosis and early detection of conditions. The ongoing advancements in molecular diagnostics, like liquid biopsies and next-generation sequencing, help in the market growth. The increasing demand for early detection of cancer and the growth in the development of personalised medicines increases the demand for IVD. The increasing demand for IVD tests for various cancers like lung, prostate cancers, breast cancers, and colorectal drives the market growth. The infectious disease segment is the fastest-growing in the market during the forecast period. The growth in infectious diseases like viral outbreaks, respiratory infections, and STDs increases demand for IVD. The increasing awareness about the early detection of infectious diseases and focus on reducing transmission increases the adoption of IVD. The increasing prevalence of hepatitis, HIV, and tuberculosis increases demand for IVD, supporting the overall market growth. Test Location Analysis: How Point of Care Segment Held the Largest Share in the In Vitro Diagnostics Market? The point of care segment held the largest revenue share in the in vitro diagnostics market in 2024. The increasing demand for faster test results and focus on reducing turnaround times increases the adoption of point of care. The increasing need for IVD tests in underserved and remote areas increases the adoption of IVD. The focus on the management of chronic conditions like cardiovascular diseases and diabetes increases demand for POC. The increasing suitability of POC in various settings like doctors' offices, hospitals, and clinics drives the market growth. The home care segment is experiencing the fastest growth in the market during the forecast period. The growing patients' preference for testing at home and the growing expansion of home-based testing help the market growth. The increasing development of automated, user-friendly, and portable IVD devices increases adoption of care. The increasing management of chronic conditions like cardiovascular diseases & diabetes increases demand for home care, supporting the overall growth of the market. End User Analysis: Why did the Hospital Segment Dominate the In Vitro Diagnostics Market? The hospitals segment dominated the in vitro diagnostics market in 2024. The high availability of a wide range of diagnostic tests and the increasing number of patients increase the adoption of hospitals. The growing demand for accurate and early diagnosis of diseases increases the demand for hospitals. The availability of advanced technologies like molecular diagnostic tools, automated analyzers, and others helps the market growth. The presence of trained personnel, well-established infrastructure, and high-quality equipment in hospitals drives the market growth. Related Topics You May Find Useful: ➢ In-Vitro Inflammatory Bowel Disease Diagnostics Market: Uncover how biomarker innovations are transforming early IBD detection ➢ Infectious Disease In-Vitro Diagnostics Market: Explore rising demand for rapid pathogen testing and accuracy-driven diagnostics ➢ In-Vitro Diagnostics Enzymes Market: See how enzyme-based assays are becoming indispensable in chronic disease detection ➢ Diagnostic Testing Market: Track how expanding cardiology testing and hospital-led diagnostics are reshaping global healthcare ➢ Next-Generation IVD Market: Dive into how AI, genomics, and precision medicine are redefining diagnostic frontiers ➢ Cancer IVD Market: Analyze how early cancer detection and immunoassays are fueling a surge in diagnostic innovation ➢ Cancer Diagnostics Market: Discover how hospital-led screening and consumables-led solutions are doubling market size by 2034 ➢ DNA Diagnostics Market: Explore how PCR tech and oncology testing are powering DNA testing's rapid growth ➢ IVD Contract Manufacturing Market: Understand how outsourcing efficiencies and consumable demand are driving diagnostic scale-up ➢ In-Vitro Colorectal Cancer Screening Tests Market: Track rising demand for non-invasive CRC screening and lab-based diagnostics In Vitro Diagnostics Market Top Companies Alere, Inc. Hoffmann-La Roche Ltd. Arkray Beckman Coulter Becton Dickinson Bio-Rad Laboratories Danaher Sysmex Corporation Abbott Laboratories Recent Developments: In August 2024, InBios launched an in vitro diagnostic test, a serological ELISA kit for strongyloidiasis. The kit provides results under 75 minutes and is intended for use only in patients with symptoms, clinical history, and signs. (Source: In June 2023, GenWorks Health launched IVD tests for malaria & dengue. The test kits include iScreen Dengue NS1 and iScreen Malaria Card Antigen. The IVD products aim to diagnose, treat, prevent, and cure seasonal diseases. (Source: In September 2023, NeoDx Biotech launched an IVD kit, the HLA-B27 RT-PCR kit for detecting autoimmune disorders. The kits help to analyze disorders like psoriasis, reactive arthritis, ankylosing spondylitis, and inflammatory bowel syndrome. (Source: Case Study: AI-Powered Molecular Diagnostics at Sunrise Labs Boosts Cancer Detection Rates Sunrise Labs, a leading diagnostic center network in Southeast Asia, faced challenges in delivering early, accurate cancer diagnoses to patients in semi-urban and rural areas. Traditional lab workflows required samples to be shipped to centralized facilities, causing delays of 3–5 days before results reached clinicians. Solution Implemented: In 2023, Sunrise Labs partnered with a global IVD leader to deploy a portable, AI-enhanced molecular diagnostics platform capable of running PCR-based oncology tests on-site. The system integrated with the lab's electronic health record (EHR) system, enabling seamless data transfer and analysis. Key Innovations: Point-of-Care Molecular Testing: Allowed oncologists to receive results within 90 minutes. AI-Driven Image Analysis: Improved detection accuracy for early-stage cancers by 18% compared to conventional lab workflows. Custom Reagent Kits: Designed for tropical climates to maintain stability without cold-chain dependency. Results Achieved: Turnaround Time Reduced: From 3–5 days to under 2 hours. Screening Uptake Increased: 35% more patients underwent cancer screening in the first year. Cost Efficiency: Operational costs dropped by 22% due to reduced logistics and sample handling. Patient Outcomes: Early detection rates for breast and cervical cancer improved, enabling earlier treatment interventions. Industry Implication: This case underscores how integrating AI with IVD molecular diagnostics can dramatically improve accessibility and patient outcomes in emerging markets, aligning with broader industry trends toward decentralization and personalized medicine. It also highlights the commercial potential for IVD players to target underserved regions with tailored product designs. In Vitro Diagnostics Market Segments Covered in the Report By Product Reagents Instruments Services By Test Location Point of Care Home Care Others By Technology Immunoassay Instruments Reagents Services Hematology Instruments Reagents Services Clinical Chemistry Instruments Reagents Services Molecular Diagnostics Instruments Reagents Services Coagulation Instruments Reagents Services Microbiology Instruments Reagents Services Others Instruments Reagents Services By Application Diabetes Cardiology Nephrology Infectious Disease Oncology Drug Testing Autoimmune Diseases Others By End User Hospitals Standalone Laboratories Academic & Medical Schools Point-of-Care Others By Region North America U.S. Canada Europe Germany UK France Italy Spain Sweden Denmark Norway Asia Pacific China Japan India South Korea Thailand Latin America Brazil Mexico Argentina Middle East & Africa South Africa UAE Saudi Arabia Kuwait Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as Immediate Delivery Available | Buy This Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@ | +1 804 441 9344 Stay Ahead with Precedence Research Subscriptions Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve. Browse Our Subscription Plans@ About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. Web: Our Trusted Data Partners: Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor | Market Stats Insight Get Recent News: For the Latest Update Follow Us: LinkedIn | Medium | Facebook | Twitter ✚ Explore More Market Intelligence from Precedence Research: ➡️ In-Vitro Fertilization Market: Explore how technological advances and rising infertility treatments are driving global IVF demand ➡️ Artificial Intelligence Diagnostics Market: See how AI-powered tools are revolutionizing accuracy and speed in clinical diagnostics ➡️ Non-Invasive Cancer Diagnostics Market: Discover how liquid biopsies and imaging innovations are reshaping cancer detection ➡️ Home Diagnostics Market: Track how convenience and digital health integration are fueling at-home testing adoption ➡️ Point-of-Care Diagnostics Market: Understand how rapid testing solutions are transforming care delivery in clinics and beyond ➡️ Infectious Respiratory Disease Diagnostics Market: Analyze demand shifts driven by pandemic preparedness and respiratory health awareness ➡️ Breast Cancer Diagnostics Market: Learn how imaging, biopsy, and AI tools are advancing early breast cancer detection ➡️ Point-of-Care Molecular Diagnostics Market: Explore how portable PCR and molecular tools are enhancing real-time diagnosis ➡️ Rapid Diagnostics Market: See how speed, accuracy, and accessibility are redefining modern diagnostics ➡️ Next-Generation Cancer Diagnostics Market: Discover how genomic profiling and precision oncology are shaping next-gen cancer testing ➡️ Tissue Diagnostics Market: Understand how histopathology innovations are improving disease characterization ➡️ Blood Transfusion Diagnostics Market: Track advances in screening technologies ensuring safer transfusion practices ➡️ Infectious Disease Diagnostics Market: Explore how rising disease outbreaks are accelerating global diagnostic capabilities ➡️ Point-of-Care Infectious Disease Diagnostics Market: See how rapid and mobile solutions are revolutionizing infectious disease management ➡️ DNA Diagnostics Market: Learn how genetic testing is unlocking new frontiers in personalized medicine ➡️ Infectious Disease In-Vitro Diagnostics Market: Discover how innovation in IVD is boosting accuracy in pathogen detectionError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
